1-cyclohexyl-4-nitro-1H-imidazole | 1193639-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-cyclohexyl-4-nitro-1H-imidazole
• 英文别名: 1-cyclohexyl-4-nitroimidazole
• CAS: 1193639-06-3
• 化学式: C₉H₁₃N₃O₂
• 分子量: 195.221
• InChiKey: QKWZMVFLHNATTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-cyclohexyl-4-nitro-1H-imidazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 23.0 ℃ 、344.75 kPa 条件下， 生成 1-cyclohexyl-1H-imidazol-4-amine
  参考文献：
  名称：

  Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer’s disease

  摘要：

  Utilizing structure-based drug design, a 4-aminoimidazole heterocyclic core was synthesized as a replacement for a 2-aminothiazole due to potential metabolically mediated toxicity. The synthetic route utilized allowed for ready synthesis of 1-substituted-4-aminoimidazoles. SAR exploration resulted in the identification of a novel cis-substituted cyclobutyl group that gave improved enzyme and cellular potency against cdk5/p25 with up to 30-fold selectivity over cdk2/cyclin E. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.019
• 作为产物：
  描述：

  溴代环己烷 、 4-硝基-3H-咪唑 在 四丁基溴化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.5h， 生成 1-cyclohexyl-4-nitro-1H-imidazole
  参考文献：
  名称：

  Discovery of WD Repeat-Containing Protein 5 (WDR5)–MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design

  摘要：

  The frequent deregulation of MYC and its elevated expression via multiple mechanisms drives cells to a tumorigenic state. Indeed, MYC is overexpressed in up to similar to 50% of human cancers and is considered a highly validated anticancer target. Recently, we discovered that WD repeat-containing protein 5 (WDR5) binds to MYC and is a critical cofactor required for the recruitment of MYC to its target genes and reported the first small molecule inhibitors of the WDR5-MYC interaction using structure-based design. These compounds display high binding affinity, but have poor physicochemical properties and are hence not suitable for in vivo studies. Herein, we conducted an NMR-based fragment screening to identify additional chemical matter and, using a structure-based approach, we merged a fragment hit with the previously reported sulfonamide series. Compounds in this series can disrupt the WDR5-MYC interaction in cells, and as a consequence, we observed a reduction of MYC localization to chromatin.

  DOI：

  10.1021/acs.jmedchem.0c00224

文献信息

• [EN] WDR5-MYC INHIBITORS<br/>[FR] INHIBITEURS DE WDR5-MYC
  申请人：UNIV VANDERBILT

  公开号：WO2021101927A1

  公开（公告）日：2021-05-27

  Substituted N-heteroaryl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject such as cancer cell proliferation.

  N-杂环磺胺化合物替代物抑制WDR5-MYC相互作用，这些化合物及其药物组合物适用于治疗主体中的疾病和状况，如癌细胞增殖。
• [EN] IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE<br/>[FR] INHIBITEURS DE LA KINASE ALK2 CONTENANT DE L'IMIDAZOLE
  申请人：BIOCRYST PHARM INC

  公开号：WO2018232094A1

  公开（公告）日：2018-12-20

  Disclosed are compounds of formula (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula (I), (II), (III), or (IV), or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

  揭示了化合物的公式（I）、（II）、（III）和（IV），以及它们的药用盐。这些化合物是ALK2激酶的抑制剂。还提供了包含公式（I）、（II）、（III）或（IV）的化合物或其药用盐的药物组合物，以及涉及使用这些化合物或其药用盐和组合物治疗和预防各种疾病和病况的方法，如纤维性骨化进行性疾病。
• IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
  申请人：Biocryst Pharmaceuticals, Inc.

  公开号：EP3638229A1

  公开（公告）日：2020-04-22